Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, tocofersolan (Vedrop®) cannot be endorsed for use within NHS Wales for the treatment of vitamin E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. |
||
|
||
Medicine details |
||
| Medicine name | tocofersolan (Vedrop®) | |
| Formulation | 50 mg/ml oral solution | |
| Reference number | 1180 | |
| Indication | For the treatment of vitamin E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. |
|
| Company | Orphan Europe (UK) Ltd | |
| BNF chapter | Nutrition & blood | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| AWMSG meeting date | 13/10/2011 | |
| Ratification by Welsh Government | 11/10/2011 | |
| Date of issue | 13/10/2011 | |